|
Title
|
|
|
|
Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| About 510% of the general adult population respond inadequately to hepatitis B vaccination. The histocompatibility leucocyte antigen (HLA) DQ2, DR3 and DR7 phenotypes have been linked with non-responsiveness to hepatitis B vaccination. A first part of our study determined the prevalence of the HLA DQ2 allele in a healthy population, aged 1550 years. We found 35% of our study population (n=1008) positive for the HLA DQ2 allele. Positive subjects for HLA DQ2 were subsequently invited to participate in a trial and were to be given either the HBsAg/AS04 hepatitis B vaccine or a licensed hepatitis B vaccine (Engerix-B).1 Both contained 20 μg of recombinant HBsAg. The HBsAg/AS04 vaccine was administered on a 0 and 6 months schedule whilst the comparator vaccine was given according to the standard 0, 1 and 6 months schedule. The experimental vaccine was formulated on a novel adjuvant containing 3′ deacylated monophosphoryl lipid A (3D-MPL) and alum. A total of 230 subjects were enrolled into the vaccination study. At month 7, 99% of the subjects had a protective titre (≥10 mIU/ml) with a geometric mean titre (GMT) of 6613 mIU/ml in the group receiving HBsAg/AS04 versus 97% seroprotected with a GMT of 2315 mIU/ml in the other group. Both vaccines, with their respective schedule, give very high seroprotection rates (>96%). Our data suggest that HLA DQ2 positivity is not a good marker for non- or poor-responsiveness. The HBsAg/AS04 vaccine was more reactogenic mainly because of an increased local reactogenicity. Both vaccines, especially HBsAg/AS04, are highly immunogenic and well tolerated by the study subjects. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Vaccine / International Society for Vaccines. - Amsterdam
| |
|
Publication
|
|
|
|
Amsterdam
:
2002
| |
|
ISSN
|
|
|
|
0264-410X
| |
|
DOI
|
|
|
|
10.1016/S0264-410X(02)00150-0
| |
|
Volume/pages
|
|
|
|
20
:19/20
(2002)
, p. 2597-2602
| |
|
ISI
|
|
|
|
000176456200023
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|